NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Accelerate Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.27 -0.39 (-2.34 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$16.07Now: $16.27▼$16.9750-Day Range$8.25MA: $11.97▼$17.4252-Week Range$4.53Now: $16.27▼$22.13Volume313,600 shsAverage Volume429,892 shsMarket Capitalization$899.26 millionP/E RatioN/ADividend YieldN/ABeta2.92 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.Read More Beat the Market (BTM) Rank™ 1.2 Analyst's Opinion Consensus RatingAccelerate Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Accelerate Diagnostics has a potential upside of 0.4% from its current price of $16.27.Amount of Analyst CoverageAccelerate Diagnostics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAccelerate Diagnostics has received 342 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAccelerate Diagnostics has received 303 “underperform” votes. (Add your “underperform” vote.)Community SentimentAccelerate Diagnostics has received 53.02% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote “Outperform” if you believe AXDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have bought 8,829.10% more of their company's stock than they have sold. Specifically, they have bought $7,143,278.00 in company stock and sold $80,000.00 in company stock.Percentage Held by Insiders44.40% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.99% of the stock of Accelerate Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accelerate Diagnostics are expected to grow in the coming year, from ($1.42) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 1.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.90 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXDX Previous Symbol CUSIPN/A CIK727207 Webacceleratediagnostics.com Phone520-365-3100Debt Debt-to-Equity RatioN/A Current Ratio16.03 Quick Ratio14.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.30 million Price / Sales96.69 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-116.21Profitability EPS (Most Recent Fiscal Year)($1.55) Net Income$-84,310,000.00 Net Margins-845.43% Return on Equity-5,681.44% Return on Assets-59.86%Miscellaneous Employees287 Outstanding Shares55,271,000Market Cap$899.26 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:AXDX Rates by TradingView Receive AXDX News and Ratings via Email Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter. Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions How has Accelerate Diagnostics' stock been impacted by COVID-19 (Coronavirus)? Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXDX shares have increased by 53.3% and is now trading at $16.27. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Accelerate Diagnostics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Accelerate Diagnostics. When is Accelerate Diagnostics' next earnings date? Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Accelerate Diagnostics. How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics Inc (NASDAQ:AXDX) released its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.39) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.39). The medical research company had revenue of $2.34 million for the quarter, compared to the consensus estimate of $2.40 million. Accelerate Diagnostics had a negative return on equity of 5,681.44% and a negative net margin of 845.43%. View Accelerate Diagnostics' earnings history. What guidance has Accelerate Diagnostics issued on next quarter's earnings? Accelerate Diagnostics updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.32 million. What price target have analysts set for AXDX? 3 equities research analysts have issued 12-month price targets for Accelerate Diagnostics' stock. Their forecasts range from $14.00 to $19.00. On average, they expect Accelerate Diagnostics' share price to reach $16.33 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price. View analysts' price targets for Accelerate Diagnostics. Has Accelerate Diagnostics been receiving favorable news coverage? Media headlines about AXDX stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Accelerate Diagnostics. Who are some of Accelerate Diagnostics' key competitors? Some companies that are related to Accelerate Diagnostics include Coherent (COHR), Horiba (HRIBF), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), BioNano Genomics (BNGO), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Precipio (PRPO), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC) and PositiveID (PSID). View all competitors. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL). Who are Accelerate Diagnostics' key executives? Accelerate Diagnostics' management team includes the following people: Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)Mr. Steve Reichling, Chief Financial Officer (Age 41)Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)Mr. Kurt Reinhardt, Head of OperationsDr. Romney M. Humphries, Chief Scientific Officer (Age 38) What is Accelerate Diagnostics' stock symbol? Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX." How do I buy shares of Accelerate Diagnostics? Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Accelerate Diagnostics' stock price today? One share of AXDX stock can currently be purchased for approximately $16.27. How big of a company is Accelerate Diagnostics? Accelerate Diagnostics has a market capitalization of $899.26 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe. What is Accelerate Diagnostics' official website? The official website for Accelerate Diagnostics is acceleratediagnostics.com. How can I contact Accelerate Diagnostics? Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
